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Abstract: Background: Treating anemia with erythropoietin (EPO) to hemoglobin (Hb) endpoints >11 g/dL may increase 
risk of serious adverse cardiovascular events. 
Methods: We used medical records data (1996-2003 from the Adolescent Spectrum of HIV Disease Project [ASD] and 
1996-2006 from the HIV Outpatient Study [HOPS]) to describe EPO prescription patterns for mildly, moderately, or 
severely anemic HIV-infected patients. We calculated proportions prescribed EPO and treated to Hb>12 g/dL, and tested 
for trends over time. We calculated median hemoglobin at first EPO prescription, and described temporal changes using 
linear regression. 
Results: Among 37,395 patients in ASD and 7,005 patients in HOPS, EPO prescription increased over time for 
moderately anemic patients; for patients with severe anemia, EPO prescription increased only among ASD patients. Hb at 
EPO prescription decreased over time in ASD patients (median=8.5 g/dL), but not in HOPS patients (median 9.5 g/dL). 
Percentage of EPO-treated patients with post-treatment Hb>12 g/dL was 18.3% in ASD and stable, and was 56.7% in 
HOPS and increased over time (p = 0.03). 
Conclusions: Through 2006, EPO prescription increased over time for patients with moderate or severe anemia. Many 
patients treated with EPO had post-treatment Hb>12 g/dL. Based on 2011 FDA recommendations, changes in previous 
prescription practices will be needed. 
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BACKGROUND 
  Anemia has long been recognized as highly prevalent 
among untreated patients with HIV infection [1-3]; 
prevalence of anemia among AIDS patients before HAART 
is as high as 90% [2]. Anemia has been consistently 
associated in observational studies with shorter survival [1-
3], and prescription of recombinant human erythropoietin 
(EPO, an erythropoesis stimulating agent, or ESA) has been 
associated with improved survival in some [1], but not all 
[4], studies of HIV-infected, anemic patients. Procrit®, an 
EPO formulation, has a label indication for treatment of 
AZT-associated anemia in patients with HIV infection [5]. 
  The FDA has issued “black box” warnings in November 
2006, and in November 2007 [6], warning of increased risk 
of thromboembolic events and progression of certain cancers 
associated with ESA prescription, particularly when ESAs 
were prescribed to treat to final hemoglobin concentrations 
(Hb) near physiological levels. Both warnings recommended 
that patients should not be treated with ESA to hemoglobin 
levels > 12 g/dL. In June 2011, an even more conservative  
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recommendation was issued by FDA, recommending that 
ESAs should not be used to increase Hb to concentrations > 
11 g/dL [7]. 
  Because Hb endpoint guidelines for treatment of anemia 
in patients with HIV infection had been based on expert 
opinion prior to the black box warnings, and because data on 
EPO prescription patterns in patients with HIV infection 
have not been reported, the extent to which historical EPO 
prescription practices of HIV care providers have been in 
line with the 2007 or 2011 FDA recommendations is unclear, 
and it is not known if revision of prescription patterns is 
needed in light of the FDA black box warnings. We sought 
to describe EPO prescription practices for patients with HIV 
infection and anemia in the United States from 1996-2006, 
using data from two large observational cohorts. 
PATIENTS AND METHODS 
  We used data from the Adult and Adolescent Spectrum 
of HIV Disease Cohort, which collected data on over 60,000 
patients in care for HIV infection in over 100 US clinics in 
11 US cities from 1990-2004; and the HIV Outpatient Study, 
which has collected data on over 8,500 patients in care for 
HIV infection in 12 clinics in 10 US cities from 1992-
present. The basic methodology and study sites for these 
cohorts have been previously described [8-10]. Both cohorts 
were reviewed and approved by the Institutional Review 114    The Open AIDS Journal, 2011, Volume 5  Sullivan et al. 
Board of the Centers for Disease Control and Prevention, 
and participating study sites. In the case of ASD, a waiver of 
informed consent was approved by the institutional review 
board. In the case of HOPS, written informed consent was 
obtained from all patient participants. In both cohorts, 
information was collected on hemoglobin measurements, 
and on prescription of ESAs. In the ASD study, data were 
collected by retrospective chart review in 6-month 
abstraction periods; in HOPS, data were collected 
prospectively at the time of each patient encounter. 
  To provide context for our analyses of EPO prescription, 
we assessed the annual prevalence of anemia (defined as at 
least one Hb < 12 g/dL in women, or < 14g/dL in men) 
among all patients in whom hemoglobin was measured from 
1996-2003 for ASD and from 1996-2006 for HOPS. We 
tested for trend in prevalence of anemia over these years in 
each dataset using the Cochran-Armitage test [11]. 
  For patients with anemia, we classified the baseline 
anemia status as mild (men: 10 g/dL  Hb < 14; women: 10 
Hb < 12), moderate (8  Hb < 10), or severe (Hb < 8); 
according to the National Cancer Institute definitions for 
severity of anemia, with the mild anemia definition modified 
to account for different reference ranges by sex [12]. For 
each severity classification, and for each cohort, we 
calculated the proportion of anemic patients prescribed EPO 
by year. We tested for trends in prevalence of treatment over 
years (1996-2003 for ASD, 1996-2003 and 1996-2006 for 
HOPS) using the Cochran-Armitage test. 
  For patients treated with EPO, we calculated the median 
hemoglobin concentration last measured before treatment, 
and the median hemoglobin concentration last measured 
during EPO treatment among patients with follow-up after 
the initial treatment, by year and cohort. The hemoglobin 
concentration at the end of therapy was defined as the last 
measured hemoglobin before the date EPO was discontinued 
for HOPS patients, and as the hemoglobin in the last 
abstraction interval during which EPO was prescribed for 
ASD patients with subsequent follow-up. We tested for 
linear trend in the hemoglobin concentrations at the end of 
Table  1.  Characteristics of Persons with at Least One Hemoglobin Measurement Included in an Analysis of Anemia and 
Erythropoietin Prescription, Adult and Adolescent Spectrum of HIV Disease Project (ASD), 1996-2003 and HIV 
Outpatient Study (HOPS), 1996-2006 
 
ASD  HOPS 
Characteristic  Number of Persons (%) 
Person-Years 
of Observation  Number of Persons (%) 
Person-Years of 
Observation 
All  37,395 (100)  119,906  7005 (100)  28,597 
Race* 
 White, non-Hispanic  11,493 (31)  38,013  3836 (55)  16,667 
 Black, non-Hispanic  18,067 (48)  57,325  2205 (31)  8,086 
 Hispanic  7,214 (19)  22,592  774 (11)  3,069 
 American Indian/Alaskan Native  354 (1)  1,130  18( <1)  43 
 Asian/Pacific Islander  202 (1)  720  40 (<1)  183 
 Other/unknown†  65 (<1)  128  132 (2)  549 
Age (Years)* 
 13-29  9,395 (25)  21,677  1060 (15)  3,817 
 30-49  25,278 (68)  80,298  5238 (75)  21,794 
  50  2,722 (7)  7,932  707 (10)  2,986 
Sex* 
 Male  25,517 (74)  86,924  5579 (80)  22,759 
 Female   9,878 (26)  32,982  1426 (20)  5,838 
HIV Acquisition Mode* 
 Male-male sex (MSM)  15,126 (40)  49,675  3998 (57)  17,040 
 Injection drug use (IDU)  7,282 (19)  22,523  788 (11)  2,896 
 MSM/IDU  3,027 (8)  9,856  157 (2)  487 
 Male-female sex  5,225 (14)  18,454  1696 (24)  6,800 
 Other known risks‡  628 (2)  2,037  173 (2)  701 
 No reported risk  6,107 (16)  17,363  193 (3)  673 
*Distribution of characteristics differs between ASD and HOPS by 
2 test, p < 0.0001. 
†Includes those reporting multiple races, and those reporting single races other than the listed categories. 
‡Includes receipt of transfusion or blood products. EPO Prescription Trends in HIV  The Open AIDS Journal, 2011, Volume 5    115 
EPO prescription by least-squares regression, with 
hemoglobin as the dependent variable and year as the 
independent variable. We also calculated the proportions of 
patients who had Hb > 12 g/dL at the end of their course of 
EPO therapy, by year and cohort. We tested for trend in 
these proportions using the Cochran-Armitage test. 
RESULTS 
  In the ASD cohort, a total of 37,395 patients contributed 
119,906 person-years [PY] of follow time. In the HOPS 
cohort, 7,005 patients contributed 28,597 PY of follow time. 
The characteristics of patients observed in the two cohorts 
differed with respect to race, age, sex, and HIV acquisition 
mode (Table 1). The overall prevalence of any anemia 
decreased significantly over time in both cohorts (Fig. 1). 
For ASD patients, prevalence decreased from 58.5% in 1996 
to 52.6% in 2003. For HOPS patients, prevalence decreased 
from 57.7% in 1996 to 37.5% in 2006. 
 
Fig. (1). Anemia was defined as a hemoglobin of <12 g/dL for 
women, and < 14 g/dL for men. P values represent trends in 
proportions by Cochran-Armitage trend test. N represents number 
of persons in each study by year. 
  Three primary findings emerged from the analysis of 
prevalence of prescription of EPO over time. First, 
prescription of EPO was consistently higher for patients with 
progressively severe anemia (Fig. 2A-C). For patients with 
mild anemia (Fig. 2A), prevalence of EPO prescription was 
lowest (all year-cohort-specific prevalences were < 4%). For 
patients with moderate anemia (Fig. 2B), year-cohort-
specific prevalences of EPO prescription ranged from 2.3%-
26%. For patients with severe anemia (Fig. 2C), year-cohort-
specific prevalences of EPO prescription ranged from 7.1%-
50%. 
  Second, the prescription of EPO was higher in HOPS 
patients than in ASD patients. For EPO prescription for 
patients with mild anemia, HOPS year-specific prevalences 
ranged from 1.1% to 3.7%; for ASD, year-specific 
prevalences ranged from 0.1% -0.8%. For EPO prescription 
for patients with moderate anemia, HOPS year-specific 
prevalences ranged from 9.6% to 26.2%; for ASD, year-
specific prevalences ranged from 2.3% -6.8%. For EPO 
prescription for patients with severe anemia, HOPS year-
specific prevalences ranged from 31.3% to 50.0%; for ASD, 
year-specific prevalences ranged from 7.1% -20.5%. 
 (A) 
(B) 
(C) 
Fig. (2). Panel A: Mild anemia was defined as hemoglobin of 10  
Hb <12 g/dL for women, and 10  Hb <14 g/dL for men. P values 
represent trends in proportions by Cochran-Armitage trend test. 
Note limited range of Y-axis scale. N’s represent number of half-
person years for ASD, and the number of persons in HOPS. Panel 
B: Moderate anemia was defined as hemoglobin of 8  Hb <10 
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g/dL. P values represent trends in proportions by Cochran-Armitage 
trend test. Note limited range of Y-axis scale. N’s represent number 
of half-person years for ASD, and the number of persons in HOPS. 
Panel C: Mild anemia was defined as hemoglobin of < 8 g/dL. P 
values represent trends in proportions by Cochran-Armitage trend 
test. Note limited range of Y-axis scale. N’s represent number of 
half-person years for ASD, and the number of persons in HOPS. 
  Third, EPO prescription increased over time for most 
cohort-severity specific analyses. EPO prescription increased 
for mildly anemic patients in HOPS, but only when the 
entire period from 1996-2006 was considered; when 
restricting the analysis to the period 1996-2003, no 
significant trend was observed (Fig. 2A). EPO prescription 
increased for moderately anemic patients in both cohorts 
(Fig. 2B). EPO prescription increased for severely anemic 
patients in ASD, but not for severely anemic patients in 
HOPS (Fig. 2C). 
  There was no trend in hemoglobin concentrations at 
initial EPO prescription in HOPS. In the ASD cohort, the 
median hemoglobin at first EPO prescription was 9.6 g/dL in 
1996 and 8.4 g/dL in 2003, which was a significant decrease 
over time (Fig. 3). Pre-treatment hemoglobin concentrations 
in HOPS were higher than in ASD, with year-specific 
medians ranging from 8.9 g/dL to 10.9 g/dL, but did not 
change over time. Median post-treatment hemoglobin 
concentrations were higher in HOPS (range 11.8 g/dL to 
13.6 g/dL) than in ASD (range 10 g/dL to 12 g/dL), but 
hemoglobin concentration at end of prescription did not 
change over time in either cohort (Fig. 3). 
Fig. (3). Anemia was defined as hemoglobin of <12 g/dL for 
women, and < 14 g/dL for men. Symbols represent median values 
for hemoglobin. Trends in hemoglobin at first prescription or end of 
prescription, by linear regression modeling hemoglobin = year: 
results were non-significant (NS: P > 0.05) for all except the trend 
in ASD pre-treatment hemoglobin concentration (*: p = 0.0002). 
N’s represent the number of persons prescribed EPO in ASD and 
HOPS. 
  The proportion of anemic patients prescribed EPO who 
had hemoglobin concentrations > 12 g/dL at the end of their 
EPO prescription was higher in HOPS (year-specific range, 
53%-71%) than ASD (range, 9%-26%). The proportion of 
patients ending therapy with hemoglobin concentrations > 12 
g/dL increased among patients in HOPS from 1996-2006, 
but did not change among patients in ASD or HOPS from 
1996-2003 (Fig. 4). 
DISCUSSION 
  Our data indicate that the EPO prescription practices in 
diverse US HIV care settings from 1996-2006 were 
inconsistent with 2007 and 2011 FDA recommendations for 
duration of ESA therapy; thus, HIV care providers should 
consider that their earlier EPO prescribing practices may 
require change in light of FDA black box warnings and 
recent recommendations about ESAs. According to our data, 
from 9% to 71% of anemic, HIV-infected patients who 
received EPO in the several years before the new warnings 
were issued were treated to hemoglobin concentrations 
above the currently recommended thresholds. While these 
patterns of prescription were not inappropriate at the time of 
our observations, they indicate the need for changes from 
earlier prescribing practices. To our knowledge, these data 
are the first detailed published data on EPO prescription 
practices for anemic patients with HIV infection. 
Fig. (4). The hemoglobin concentration at the end of therapy was 
defined as the last measured hemoglobin before the date EPO was 
discontinued for HOPS patients, and as the hemoglobin in the last 
abstraction interval during which EPO was prescribed for ASD 
patients with subsequent follow-up. 
  Recommendations on practice strategies and treatment 
guidelines for use of EPO in patients with anemia and HIV 
infection were not definitive during the period covered by 
our report. The label indication for Procrit® in HIV-infected 
patients was and still is for AZT-related anemia, but research 
reports [13] and clinical HIV treatment guidelines [14] have 
broadly recommended consideration of EPO therapy for 
anemia without identified cause, even when patients are not 
prescribed AZT. Most anemia in HIV-infected persons in the 
United States is probably attributable to the anemia of HIV 
infection (anemia of chronic disease) [4], especially as 
prescriptions of AZT have decreased in recent years. 
  Previous recommendations for EPO treatment of anemia 
have been motivated by a large number of published reports 
describing the association of anemia and shorter survival 
(reviewed in 2002 [15]), and by information about quality of 
life and its relationship to anemia [16]. In 2000, an expert 
panel concluded that the target hemoglobin for EPO therapy 
was 12 g/dL for men and 11 g/dL for women [17], but that 
EPO treatment should be discontinued only if hemoglobin 
concentration rose to > 13 g/dL during EPO therapy [14, 17]. 
Thus, for the many patients in our analysis who were treated 
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to hemoglobin concentrations up to 13 g/dL, the EPO 
prescription practice may have been within recommended 
practice standards as documented by published treatment 
recommendations and published expert opinion. 
  Several new pieces of information have led to a 
reconsideration of EPO prescription practices, both from the 
regulatory point of view and based on meta-analytic data 
about survival and erythropoietin treatment. In 2006, trials of 
EPO in patients with chronic kidney disease [18, 19] 
demonstrated no improvement of cardiovascular outcomes, 
and, in one trial, a higher risk for a composite negative study 
endpoint (e.g., death or cardiac event). In 2007, preliminary 
data from an unpublished randomized trial of an ESA in 
spinal surgery patients found a higher incidence of deep 
venous thrombosis among EPO-treated patients [20], and 
several studies reported to FDA have suggested that ESA 
prescription may be associated with progression of certain 
cancers, including breast cancer, cervical cancer, and head 
and neck tumors [20, 21]. Further, a 2007 meta-analysis of 
data on anemia, survival, and EPO therapy for patients with 
HIV suggested that treatment with EPO did not improve 
survival [22]. We did not assess in our analysis endpoints, 
such as thrombotic events or cancer progression, that are 
potentially EPO-related, and to the best of our knowledge, 
there are not data directly demonstrating increased risk for 
these events associated with EPO prescription in HIV-
infected patients. 
  In other disease conditions, there has been evidence of 
more aggressive treatment of anemia with ESA in the past 15 
years. In a cohort of renal dialysis patients with anemia 
followed through the United States Renal Data System 
(USRDS), in 2005 57% of patients were treated with an ESA 
to hemoglobin concentrations > 13 g/dL; from 1994-2005, 
mean weekly ESA dose in incident dialysis patients doubled, 
and the mean monthly hemoglobin concentrations of all 
patients in care increased by nearly 20% [23]. The increased 
use of ESA therapy for anemia in renal dialysis patients even 
caught the attention of the popular press; the New York 
Times reported that mean dosages of EPO prescribed in the 
United States were much higher than prescribed doses in 
other countries, characterizing the US prescribing practices 
as aggressive [24]. We found that, among patients in our 
cohorts, the prevalence of EPO prescription was as high as 
among patients in the USRDS report, and that increases in 
EPO prescription were mostly observed among patients with 
moderate or severe anemia. The proportions of anemic 
HOPS patients treated to hemoglobin concentrations   
> 12 g/dL from 2003-2006 ranged from 53-71%, similar to 
the USRDS findings of “overshoot”, suggesting that 
prescription patterns in the two groups may be similar. 
  There were consistent differences between HOPS and 
ASD patients in our outcomes of EPO prescription, and 
hemoglobin concentrations at treatment initiation and 
discontinuation. Generally, patients in the ASD cohort were 
prescribed less EPO, were prescribed EPO at more advanced 
stages of anemia, and were treated with EPO to lower ending 
hemoglobin concentrations. Although both ASD and HOPS 
include a variety of public and private treatment facilities, 
the facilities included in the ASD cohort are more inclusive 
of public treatment facilities than are the HOPS treatment 
settings, and it is likely that some of the differences in EPO 
prescription between the two cohorts reflect differences in 
insurance status between patients in the two cohorts. 
Because the ASD cohort did not collect complete 
information about insurance status, we could not address this 
possibility directly. 
  Our analysis is subject to several limitations. First, 
despite the large number of diverse clinical settings included 
in the ASD and HOPS cohorts, the facilities and their 
patients are not representative of all patients in care for HIV 
infection in the United States. Also, because our studies were 
observational, we did not specify when hemoglobin 
measurements were taken, and the times from the 
hemoglobin measurements to initiation or discontinuation of 
EPO prescription were variable. In the ASD cohort, EPO 
prescription was documented only as occurring within a 6-
month interval and in some cases only one hemoglobin 
measurement may have been recorded per 6 month interval 
in ASD; this led to less analytic precision than in the HOPS 
analysis, for which precise dates and length of prescription 
were abstracted. It is possible that other underlying 
indications for EPO therapy, such as chronic renal disease, 
may have increased in the ASD and HOPS patient 
populations over time, and we did not account for this in our 
analysis. Also, our datasets did not have additional data, such 
as MCV, serum EPO concentrations, and other 
measurements of iron that would have allowed us to classify 
the likely causes of anemia, so we could not stratify our 
analysis by etiology of anemia. We also did not analyze data 
on sequelae or patient well-being as it related to ESA dosing. 
Finally, our analyses did not span the period in 2006-2007 
when the original FDA black box warnings were issued, so 
we cannot evaluate whether prescription patterns have 
changed since that time. 
  Our study documents that from 1996-2006, HIV care 
providers treated anemia, especially moderate and severe 
anemia, aggressively with EPO. These changes occurred 
during a period of time when multiple lines of evidence 
suggested that managing anemia more aggressively bore 
clinical consideration, and during which anemic patients (not 
necessarily HIV-infected) in renal dialysis were treated for 
anemia with increasing aggressiveness. However, these data 
taken together with our current understanding of the risks 
associated with treatment of anemia to hemoglobin 
concentrations > 11 g/dL in other populations suggest that 
the EPO prescription patterns of HIV care providers should 
be substantially more conservative than they were in our 
historical analysis. Future analyses of observational clinical 
databases (either cohort or representative cross sectional 
surveys [25]) may be helpful in documenting changes in 
EPO prescription practices following the FDA warnings in 
2006 and 2007, and the revised FDA recommendations for 
dosing in 2011. 
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